Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients

This study has been terminated.
(Enrollment target not reached)
Sponsor:
Information provided by (Responsible Party):
Dompé Farmaceutici S.p.A
ClinicalTrials.gov Identifier:
NCT01861054
First received: April 18, 2013
Last updated: February 2, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: March 2016
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)